Literature DB >> 7957782

Prevalence of anti-HCV in institutionalised mentally handicapped subjects.

F Pregliasco, A Conti.   

Abstract

Data on the prevalence of antibody to hepatitis C virus among 278 subjects in an institution for the mentally handicapped were analysed by risk factors. A prevalence of 4% was found, higher than blood donors belonging to the same area (1.4%). No differences in prevalence with regard the length of residence, age, sex, degree of retardation or for presence of HBV markers were observed.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7957782     DOI： 10.1007/BF01717464

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN： 0393-2990            Impact factor:   8.082


  6 in total

1.  Hepatitis C in institutionalized children.

Authors:  R Vranckx; P Van Damme
Journal:  N Engl J Med       Date:  1990-07-05       Impact factor: 91.245

2.  Hepatitis C virus antibody.

Authors:  P P Mortimer; B J Cohen; P A Litton; E M Vandervelde; M F Bassendine; A M Brind; M H Hambling
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  Antibodies to hepatitis C virus in blood donors.

Authors:  P Ferroni; A Tagger; M L Ribero; A Grossi; F Pregliasco; M L Pasquali; S Salvaneschi
Journal:  Eur J Epidemiol       Date:  1990-09       Impact factor: 8.082

4.  Hepatitis B vaccination in Down's syndrome and other mentally retarded patients.

Authors:  R A Heijtink; P De Jong; S W Schalm; N Masurel
Journal:  Hepatology       Date:  1984 Jul-Aug       Impact factor: 17.425

5.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

6.  Prevalence of hepatitis B infection among residents of an institution for the mentally retarded.

Authors:  R K Chaudhary; E Perry; T E Cleary
Journal:  Am J Epidemiol       Date:  1977-02       Impact factor: 4.897
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.